Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BHT high
Drug: BI 54903 XX high
Drug: BI 54903 XX medium 2
Drug: BI 54903 XX low
Drug: BHT low
Drug: BHT medium
Drug: Ciclesonide
Drug: BI 54903 XX medium 1

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02221375

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/Metformin FDC
Drug: Linagliptin
Drug: Metformin

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT02221414

Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Placebo for RMT-B
Drug: Placebo for HFA-MDI
Drug: BHT 0.1%
Drug: BHT 0.5%

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 61

Registration Number: NCT02220673

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: BI 1744 CL + BI 54903 XX FDC
Drug: Placebo
Drug: BI 54903 XX

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02220660

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/Metformin FDC
Drug: Linagliptin
Drug: Metformin

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02221401

Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Telmisartan
Drug: Lacidipine

First Posted Date: 2014-08-18

Last Posted Date: 2014-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02218684

Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Brotizolam
Drug: WE941 OD tablets

First Posted Date: 2014-08-18

Last Posted Date: 2014-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02218658

Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WE 941 OD tablets

First Posted Date: 2014-08-18

Last Posted Date: 2014-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02218671

Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) Taken With Water in Healthy Adult Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WE 941 OD tablets
Drug: Brotizolam

First Posted Date: 2014-08-18

Last Posted Date: 2014-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02218645

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 653048 H3PO4 high dose capsule
Drug: Placebo
Drug: BI 653048 H3PO4 low dose capsule
Drug: BI 653048 H3PO4 solution

First Posted Date: 2014-08-15

Last Posted Date: 2014-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02217644

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy